Transcend Capital Advisors’s ImmunityBio IBRX Stock Holding History

Transcend Capital Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,100	Closed	-$108K	–	839
2026 Q1	$108K	Buy	+14,100	New	+$96.5K	0.01%	705

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Transcend Capital Advisors's IBRX Position: Q2 2026 in Review

Transcend Capital Advisors sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 14,100 shares — an estimated $108K sold.

Transcend Capital Advisors first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $108K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Transcend Capital Advisors reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Transcend Capital Advisors sold 14,100 ImmunityBio shares in Q2 2026, an estimated $108K.
Transcend Capital Advisors first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
Transcend Capital Advisors's ImmunityBio position peaked at $108K in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.